01—Abstract
Summary
Summary of the 10-Q filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines Ltd. reported a strong second quarter for 2025, demonstrating significant year-over-year revenue growth driven by its key oncology products.
Total revenues increased by 41.6% to $1.32 billiona, primarily fueled by a 41.4% rise in product revenue, with BRUKINSA® sales alone surging 49.0% to $950 million globally. This robust top-line growth, coupled with improving gross margins and disciplined operating expense management, allowed the company to achieve a positive GAAP net income of $94.3 million, a substantial improvement from the net loss in the prior year's comparable period. The company also highlighted significant progress in its pipeline, anticipating over 20 R&D milestones in the next 18 months.
Operationally, BeOne Medicines is effectively scaling its commercial capabilities, particularly in the U.S. and Europe, which are key drivers for BRUKINSA's continued market leadership. The company's strategic focus on expanding its oncology franchise is evident in its R&D day announcements and positive clinical development updates.
While R&D and SG&A expenses increased to support this growth, they were managed effectively relative to revenue growth, leading to improved operating leverage and a shift from an operating loss to an operating profit. The company also successfully completed its redomiciliation to Switzerland and updated its name, marking a significant corporate milestone.
02—Key points
Key Highlights
- Total revenues increased by 41.6% to $1.32 billion for Q2 2025 compared to Q2 2024.
- Global BRUKINSA® revenues grew by 49.0% to $950 million in Q2 2025.
- Achieved positive GAAP net income of $94.3 million for Q2 2025, a significant turnaround from a net loss in Q2 2024.
- Gross margin on product sales improved to 87.4% in Q2 2025 from 85.0% in Q2 2024.
- Research and Development expenses increased by 15.5% to $524.9 million, supporting pipeline advancement.
- Selling, General, and Administrative expenses increased by 21.2% to $537.9 million, reflecting investment in global commercial expansion.
- The company anticipates over 20 R&D milestones in the next 18 months.
- Completed redomiciliation to Switzerland and changed its legal name to BeOne Medicines Ltd. on May 27, 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, BeOne Medicines Ltd. kept $0.07.
- Revenue$1.32B100.0%
- Cost of revenue−$164.6M12.5%
- Gross profit$1.15B87.5%
- Operating costs−$1.06B80.8%
- Operating income$87.9M6.7%
- Interest, other & tax$6.4M0.5%
- Net income$94.3M7.2%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 6, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $1.32B$929.17M | +41.6% |
| Gross Profit | $1.15B$791.03M | +45.5% |
| R&D Expenses | $524.90M$454.47M | +15.5% |
| SG&A Expenses | $537.91M$443.73M | +21.2% |
| Operating Expenses | $1.06B$898.20M | +18.3% |
| Operating Income | $87.89M-$107.16M | +182.0% |
| Interest Expense | $12.05M$13.23M | −9.0% |
| Net Income | $94.32M-$120.41M | +178.3% |
| EPS (Basic) | $0.07$-0.09 | +177.8% |
| EPS (Diluted) | $0.06$-0.09 | +166.7% |
| Shares Outstanding (Basic) | 1.41B1.36B | +3.5% |
| Shares Outstanding (Diluted) | 1.46B1.36B | +7.5% |
05—Questions
Frequently Asked Questions
What drove the significant revenue growth in the quarter?
The substantial revenue growth was primarily driven by strong performance of BeOne Medicines' key oncology products, particularly BRUKINSA®, which saw a 49.0% increase in global sales. Growth in TEVIMBRA® and in-licensed Amgen products also contributed positively to the overall revenue increase.
How is the company managing its operating expenses while investing in growth?
BeOne Medicines is demonstrating improved operating leverage. While R&D and SG&A expenses increased to support pipeline development and global commercial expansion, the rate of increase was lower than revenue growth. This efficient expense management, combined with strong gross margins, allowed the company to transition from a net loss in the prior year period to a net profit in Q2 2025.
What is the outlook for the company's pipeline?
The company has a robust pipeline and anticipates significant progress, having outlined more than 20 expected R&D milestones in the next 18 months across both hematology and solid tumor indications. This includes advancements with key drug candidates and the potential for new trial initiations.
What was the impact of the redomiciliation to Switzerland?
The redomiciliation to Switzerland, completed on May 27, 2025, is a significant corporate milestone. While not directly impacting the financial results for this period, it marks a strategic move for the company's long-term evolution. The company also changed its legal name from BeiGene, Ltd. to BeOne Medicines Ltd. as part of this process.
06—Continue